ATE215380T1 - Verwendung von interleukin-12 fuer die verhinderung von transplantat gegen empfaengerkrankheit - Google Patents

Verwendung von interleukin-12 fuer die verhinderung von transplantat gegen empfaengerkrankheit

Info

Publication number
ATE215380T1
ATE215380T1 AT95908628T AT95908628T ATE215380T1 AT E215380 T1 ATE215380 T1 AT E215380T1 AT 95908628 T AT95908628 T AT 95908628T AT 95908628 T AT95908628 T AT 95908628T AT E215380 T1 ATE215380 T1 AT E215380T1
Authority
AT
Austria
Prior art keywords
interleukin
prevention
against recipient
transplant against
recipient disease
Prior art date
Application number
AT95908628T
Other languages
English (en)
Inventor
Stanley F Wolf
Megan Sykes
Original Assignee
Genetics Inst
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Inst, Gen Hospital Corp filed Critical Genetics Inst
Application granted granted Critical
Publication of ATE215380T1 publication Critical patent/ATE215380T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5434IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/208IL-12
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT95908628T 1994-01-21 1995-01-20 Verwendung von interleukin-12 fuer die verhinderung von transplantat gegen empfaengerkrankheit ATE215380T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/186,529 US5573764A (en) 1994-01-21 1994-01-21 Use of interleukin-12 to prevent graft versus host disease
PCT/US1995/000879 WO1995019786A1 (en) 1994-01-21 1995-01-20 Use of interleukin-12 to prevent graft versus host disease

Publications (1)

Publication Number Publication Date
ATE215380T1 true ATE215380T1 (de) 2002-04-15

Family

ID=22685309

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95908628T ATE215380T1 (de) 1994-01-21 1995-01-20 Verwendung von interleukin-12 fuer die verhinderung von transplantat gegen empfaengerkrankheit

Country Status (14)

Country Link
US (2) US5573764A (de)
EP (1) EP0739212B1 (de)
JP (1) JP3825043B2 (de)
AT (1) ATE215380T1 (de)
AU (1) AU698410B2 (de)
CA (1) CA2181568C (de)
DE (1) DE69526206T2 (de)
DK (1) DK0739212T3 (de)
ES (1) ES2179096T3 (de)
IL (1) IL112373A (de)
PT (1) PT739212E (de)
TW (1) TW349021B (de)
WO (1) WO1995019786A1 (de)
ZA (1) ZA95463B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease
US5674483A (en) * 1995-01-31 1997-10-07 National Jewish Medical And Research Center Treatment for diseases involving inflammation
JP2000510813A (ja) * 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Il−12用処方
WO1997016203A1 (en) * 1995-11-01 1997-05-09 Genetics Institute, Inc. Methods for administration of il-12
CA2268365A1 (en) * 1996-10-18 1998-04-30 Jeff Nordstrom Il-12 gene expression and delivery systems and uses
EP0931156A2 (de) * 1996-10-18 1999-07-28 Valentis Inc. Genexpressions- und transfersysteme und deren verwendungen
AU6150498A (en) * 1997-02-07 1998-08-26 Wistar Institute, The Methods and compositions for the inhibition of interleukin-12 production
EP0919241B1 (de) * 1997-05-16 2004-08-04 Toray Industries, Inc. Medikament, behandlungsmethode, prophylaktikum und prophylaxe gegen immunologische erkrankungen von hunden und katzen
EP1516630A3 (de) * 1997-10-31 2006-05-03 Wyeth Verwendung von anti-il-12 Antikörpern bei Transplantationsabstossungen
US6080399A (en) * 1998-04-23 2000-06-27 Arch Development Corporation Vaccine adjuvants for immunotherapy of melanoma
US7115712B1 (en) * 1999-12-02 2006-10-03 Maxygen, Inc. Cytokine polypeptides
US7638496B2 (en) 2000-02-15 2009-12-29 Valeant Pharmaceuticals North America Nucleoside analogs with carboxamidine modified monocyclic base
US7718196B2 (en) * 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
US20040241153A1 (en) * 2001-08-31 2004-12-02 Fowler Daniel H. Methods of generating human cd4+ th1 cells
US20040258661A1 (en) * 2001-10-31 2004-12-23 Daniel Fowler Generation of use of tc1 and tc2 cells
WO2003004625A1 (en) * 2001-07-02 2003-01-16 The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services Methods of generating human cd4+ th2 cells and uses thereof
DE10248141B4 (de) * 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nukleinsäuren und deren Verwendung für die Gentherapie
US7939058B2 (en) 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
WO2009048560A1 (en) * 2007-10-08 2009-04-16 Intrexon Corporation Engineered dendritic cells and uses for the treatment of cancer
US20100272863A1 (en) * 2009-04-24 2010-10-28 Griebel Jonathan M Soft shaped tortillas
JP6267510B2 (ja) 2010-05-18 2018-01-24 ニューメディシンズ,インコーポレーテッド 造血を増強するためのil−12製剤
CA2839261A1 (en) 2011-06-13 2012-12-20 Neumedicines, Inc. Mitigation of cutaneous injury with il-12
WO2013016634A1 (en) 2011-07-27 2013-01-31 Neumedicines, Inc. Use of il-12 to generate endogenous erythropoietin
EP2766035B1 (de) * 2011-10-11 2018-03-28 Universität Zürich Prorektorat MNW Kombinationsmedikament mit il-12 und einem mittel zur blockade von t-zellen-hemmer-molekülen zur tumortherapie
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
US9636381B2 (en) 2012-01-18 2017-05-02 Neumedicines, Inc. Methods for radiation protection by administering IL-12
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
MX2022012823A (es) * 2020-04-17 2023-01-04 Univ Leland Stanford Junior Polipéptidos modificados de il-12 e il-23 y usos de los mismos.
US20220162638A1 (en) * 2020-10-13 2022-05-26 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA931489B (en) * 1992-03-04 1993-10-28 Schering Corp Use of interleuken-10 to suppress graft-vs-host disease
DE4315127A1 (de) * 1993-05-07 1994-11-10 Behringwerke Ag Arzneimittel enthaltend die Untereinheit p40 von Interleukin-12
US5573764A (en) * 1994-01-21 1996-11-12 Genetics Institute, Inc. Use of interleukin-12 to prevent graft versus host disease

Also Published As

Publication number Publication date
PT739212E (pt) 2002-08-30
IL112373A0 (en) 1995-03-30
CA2181568A1 (en) 1995-07-27
JPH09508371A (ja) 1997-08-26
US5573764A (en) 1996-11-12
AU698410B2 (en) 1998-10-29
IL112373A (en) 2006-08-01
WO1995019786A1 (en) 1995-07-27
TW349021B (en) 1999-01-01
DE69526206D1 (de) 2002-05-08
EP0739212B1 (de) 2002-04-03
ES2179096T3 (es) 2003-01-16
CA2181568C (en) 2007-09-18
ZA95463B (en) 1995-09-27
JP3825043B2 (ja) 2006-09-20
EP0739212A1 (de) 1996-10-30
AU1687595A (en) 1995-08-08
DE69526206T2 (de) 2002-11-21
DK0739212T3 (da) 2002-06-03
US5756085A (en) 1998-05-26

Similar Documents

Publication Publication Date Title
ATE215380T1 (de) Verwendung von interleukin-12 fuer die verhinderung von transplantat gegen empfaengerkrankheit
PL323825A1 (en) Peptidyloheterocycli compounds useful in treating diorders associated with thrombosin
IL144294A0 (en) P53 inhibitors and therapeutic use of the same
NO924619D0 (no) (+)-alfa-(2,3-dimetoksyfenyl)-1-(2-(4-fluorfenyl)ethyl)-4-piperidinmetanol
TR199701212T1 (xx) �drar� tutamama halinin tedavisi i�in alfa IL- agonistlerinin kullan�lmas�.
DK0755249T3 (da) Anvendelse af Maillard-reaktionsinhibitor til behandling af amyloidose-baseret sygdom
TW200505434A (en) Therapeutic treatment
ATE185066T1 (de) Lösung zur verwendung gegen den pilzbefall von nägeln
NO20006357D0 (no) Anvendelse av optisk ren (+)-norcisaprid ved behandling av apné, bulimi og andre sykdommer
ID27414A (id) Penghambat-penghambat non-peptidil dari pengikat sel tergantung vla-4 yang bermanfaat dalam pengobatan penyakit-penyakit inflamasi, autoimun dan pernafasan
ATE159424T1 (de) Verwendung von hydroxylierte carbonsäure zur behandlung von nägeln
ZA975288B (en) The use of TCET in the prophylaxis and treatment of allergies.
WO1996002240A3 (en) Use of inhibitors of human s-cd23
DE59004277D1 (de) Copolymerisat sowie dessen Verwendung.
WO1996005845A3 (en) Treatment of disease and conditions associated with macrophage infiltration in particular stroke and myocardial infarction
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE243036T1 (de) Levobupivacain und dessen verwendung als anästhetikum bei schwangeren frauen
NO20006358D0 (no) Anvendelse av optisk ren (-)-norcisaprid ved behandling av apné, bulimi og andre sykdommer
ZA9711468B (en) New use of comt inhibitors
NO902620D0 (no) Drivstoff og brenselbehandling.
TR200003084T2 (tr) Paroxetine askorbat
SE9403861D0 (sv) Novel medicinal use
ZA916313B (en) New use of a monoclonal antibody
ATE294590T1 (de) Verwendung von interleukin-11 zur behandlung von hämoragischem schock
TR200103662T2 (tr) Yeni kalpainler ve bunların kullanılması

Legal Events

Date Code Title Description
EEFA Change of the company name